Geron (GERN) Q4 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy GERN?
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GERN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GERN
Wall Street analysts forecast GERN stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.390
Low
4.00
Averages
4.00
High
4.00
Current: 1.390
Low
4.00
Averages
4.00
High
4.00
About GERN
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Geron Reports Q1 Earnings Beat Expectations
- Earnings Highlights: Geron reported a Q1 GAAP EPS of -$0.01, beating expectations by $0.01, with revenue of $51.84 million, reflecting a 30.9% year-over-year increase and surpassing estimates by $1.25 million, indicating a positive trend in financial performance.
- Demand Growth: RYTELO demand grew by 6% in Q1 2026 compared to Q4 2025, suggesting an increase in product acceptance in the market, which may lay the groundwork for future sales growth.
- Customer Base Expansion: The number of ordering accounts increased by approximately 12% in Q1 2026 to about 1,450, reflecting success in customer acquisition and market penetration strategies.
- Future Outlook: The company expects RYTELO net product revenue for fiscal year 2026 to be in the range of $220 million to $240 million, while total operating expenses are anticipated to be between $230 million and $240 million, demonstrating cautious optimism regarding future financial health.
See More
Geron Corporation Q1 Earnings Announcement Scheduled
- Earnings Release Date: Geron Corporation is set to announce its Q1 earnings on May 6 before market open, with a consensus EPS estimate of -$0.02, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $50.59 million, reflecting a 27.8% year-over-year increase, which, despite minimal overall sales growth, may indicate a gradual market acceptance of its products.
- Earnings Forecast Revisions: Over the past three months, EPS estimates have seen one upward revision with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although revenue estimates have faced four downward revisions, highlighting concerns about revenue growth.
- Market Reaction: Geron has previously missed earnings expectations, resulting in a decline in stock price, and analysts' views on its future performance have become more conservative, reflecting investor skepticism about the company's outlook.
See More
Geron Corporation Misses Q4 Earnings Forecasts, Shares Drop 15%
- Earnings Miss: Geron Corporation reported a Q4 2025 net loss of $0.05 per share on $48 million in revenue, falling short of analysts' expectations by over $2.4 million, indicating stagnation in revenue growth that could undermine investor confidence.
- Widening Losses: The company's total costs and operating expenses rose approximately 2% year-over-year to $254.7 million, while the net loss for Q4 widened by about 23% to $31.1 million, primarily due to a $17 million restructuring expense, reflecting challenges in cost management.
- Significant Revenue Growth: Despite the losses, Geron's full-year revenue more than doubled to $183.9 million, driven by FDA approval of Rytelo for a rare blood cancer, showcasing the market potential of new products and laying a foundation for future growth.
- Cautious Outlook: The company projects full-year net product revenue for Rytelo to be between $220 million and $240 million, with operating expenses expected to range from $230 million to $240 million, indicating a need to manage costs and competitive pressures despite growth expectations.
See More
Geron Corporation to Announce Q4 Earnings on February 25
- Earnings Announcement Schedule: Geron Corporation is set to release its Q4 earnings report on February 25 before market open, with consensus EPS estimates at -$0.04 and revenue expectations at $50.43 million, reflecting a 6.1% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, Geron's EPS estimates have seen no upward revisions and one downward revision, while revenue estimates also experienced no upward revisions and one downward revision, indicating market caution regarding its profitability.
- Strategic Restructuring Plan: Geron is implementing a strategic restructuring plan focused on Rytelo growth, aiming to optimize resource allocation to enhance overall operational efficiency and lay the groundwork for revenue growth in 2026.
- Market Analyst Perspectives: Analysts maintain a cautious outlook on Geron's future, suggesting that the company must effectively manage operating expenses during the restructuring process to achieve better financial performance in 2026.
See More
Warning Signs for Overbought Tech Stocks
- Overbought Signals: As of February 20, 2026, two stocks in the information technology sector, Daktronics Inc (NASDAQ:DAKT) and Fastly Inc (NASDAQ:FSLY), are showing overbought signals with RSI indicators exceeding 70, warning investors to exercise caution.
- Momentum Indicator Analysis: The RSI, a momentum indicator that compares a stock's strength on up days versus down days, aids traders in assessing short-term performance; the current overbought status may lead to price corrections, impacting investor decisions.
- Market Reaction Warning: An overbought condition typically indicates excessive demand for these stocks, potentially resulting in increased price volatility in the short term, prompting investors to be aware of potential risks and adjust strategies accordingly.
- Investor Strategy Adjustment: Given the current overbought signals, investors may need to reassess their positions, considering short-term reductions or adopting more conservative investment strategies to mitigate potential market corrections.
See More
Geron Corporation (GERN) Projects $220M-$240M Net Revenue for Rytelo in 2026
- Financial Guidance: Geron Corporation anticipates net product revenue for Rytelo to range between $220 million and $240 million in 2026, reflecting the company's confidence in future revenue growth while also indicating efforts to reduce operating expenses.
- Operating Expense Control: Total operating expenses are expected to be between $230 million and $240 million in 2026, demonstrating progress in optimizing cost structures, thereby laying the groundwork for future profitability.
- Product Approval Status: Rytelo has been approved in the U.S. for treating lower-risk myelodysplastic syndrome (LR-MDS) with transfusion-dependent anemia and in the EU as a monotherapy for adult patients, showcasing its market potential.
- Market Outlook: With Rytelo's approvals across multiple regions, Geron Corporation is poised to seize market opportunities for treating low-risk MDS patients in the coming years, further driving overall company growth.
See More
Geron Reports Q1 Earnings Beat Expectations
- Earnings Highlights: Geron reported a Q1 GAAP EPS of -$0.01, beating expectations by $0.01, with revenue of $51.84 million, reflecting a 30.9% year-over-year increase and surpassing estimates by $1.25 million, indicating a positive trend in financial performance.
- Demand Growth: RYTELO demand grew by 6% in Q1 2026 compared to Q4 2025, suggesting an increase in product acceptance in the market, which may lay the groundwork for future sales growth.
- Customer Base Expansion: The number of ordering accounts increased by approximately 12% in Q1 2026 to about 1,450, reflecting success in customer acquisition and market penetration strategies.
- Future Outlook: The company expects RYTELO net product revenue for fiscal year 2026 to be in the range of $220 million to $240 million, while total operating expenses are anticipated to be between $230 million and $240 million, demonstrating cautious optimism regarding future financial health.
See More
Geron Corporation Q1 Earnings Announcement Scheduled
- Earnings Release Date: Geron Corporation is set to announce its Q1 earnings on May 6 before market open, with a consensus EPS estimate of -$0.02, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $50.59 million, reflecting a 27.8% year-over-year increase, which, despite minimal overall sales growth, may indicate a gradual market acceptance of its products.
- Earnings Forecast Revisions: Over the past three months, EPS estimates have seen one upward revision with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although revenue estimates have faced four downward revisions, highlighting concerns about revenue growth.
- Market Reaction: Geron has previously missed earnings expectations, resulting in a decline in stock price, and analysts' views on its future performance have become more conservative, reflecting investor skepticism about the company's outlook.
See More
Geron Corporation Misses Q4 Earnings Forecasts, Shares Drop 15%
- Earnings Miss: Geron Corporation reported a Q4 2025 net loss of $0.05 per share on $48 million in revenue, falling short of analysts' expectations by over $2.4 million, indicating stagnation in revenue growth that could undermine investor confidence.
- Widening Losses: The company's total costs and operating expenses rose approximately 2% year-over-year to $254.7 million, while the net loss for Q4 widened by about 23% to $31.1 million, primarily due to a $17 million restructuring expense, reflecting challenges in cost management.
- Significant Revenue Growth: Despite the losses, Geron's full-year revenue more than doubled to $183.9 million, driven by FDA approval of Rytelo for a rare blood cancer, showcasing the market potential of new products and laying a foundation for future growth.
- Cautious Outlook: The company projects full-year net product revenue for Rytelo to be between $220 million and $240 million, with operating expenses expected to range from $230 million to $240 million, indicating a need to manage costs and competitive pressures despite growth expectations.
See More
Geron Corporation to Announce Q4 Earnings on February 25
- Earnings Announcement Schedule: Geron Corporation is set to release its Q4 earnings report on February 25 before market open, with consensus EPS estimates at -$0.04 and revenue expectations at $50.43 million, reflecting a 6.1% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, Geron's EPS estimates have seen no upward revisions and one downward revision, while revenue estimates also experienced no upward revisions and one downward revision, indicating market caution regarding its profitability.
- Strategic Restructuring Plan: Geron is implementing a strategic restructuring plan focused on Rytelo growth, aiming to optimize resource allocation to enhance overall operational efficiency and lay the groundwork for revenue growth in 2026.
- Market Analyst Perspectives: Analysts maintain a cautious outlook on Geron's future, suggesting that the company must effectively manage operating expenses during the restructuring process to achieve better financial performance in 2026.
See More
Warning Signs for Overbought Tech Stocks
- Overbought Signals: As of February 20, 2026, two stocks in the information technology sector, Daktronics Inc (NASDAQ:DAKT) and Fastly Inc (NASDAQ:FSLY), are showing overbought signals with RSI indicators exceeding 70, warning investors to exercise caution.
- Momentum Indicator Analysis: The RSI, a momentum indicator that compares a stock's strength on up days versus down days, aids traders in assessing short-term performance; the current overbought status may lead to price corrections, impacting investor decisions.
- Market Reaction Warning: An overbought condition typically indicates excessive demand for these stocks, potentially resulting in increased price volatility in the short term, prompting investors to be aware of potential risks and adjust strategies accordingly.
- Investor Strategy Adjustment: Given the current overbought signals, investors may need to reassess their positions, considering short-term reductions or adopting more conservative investment strategies to mitigate potential market corrections.
See More
Geron Corporation (GERN) Projects $220M-$240M Net Revenue for Rytelo in 2026
- Financial Guidance: Geron Corporation anticipates net product revenue for Rytelo to range between $220 million and $240 million in 2026, reflecting the company's confidence in future revenue growth while also indicating efforts to reduce operating expenses.
- Operating Expense Control: Total operating expenses are expected to be between $230 million and $240 million in 2026, demonstrating progress in optimizing cost structures, thereby laying the groundwork for future profitability.
- Product Approval Status: Rytelo has been approved in the U.S. for treating lower-risk myelodysplastic syndrome (LR-MDS) with transfusion-dependent anemia and in the EU as a monotherapy for adult patients, showcasing its market potential.
- Market Outlook: With Rytelo's approvals across multiple regions, Geron Corporation is poised to seize market opportunities for treating low-risk MDS patients in the coming years, further driving overall company growth.
See More
